Brief: Instil Bio - On March 28, Entered Open Market Sale Agreement With Jefferies - SEC Filing
Brief: Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
U.S. RESEARCH ROUNDUP-CNX Resources, Inari Medical, Royal Gold
Brief: Instil Bio Subsidiary Secures $85.6 Million Term Loan From Midland National Life Insurance Co
Brief: Instil Bio Inc Files For Mixed Shelf Offering Of Up To $200 Million - SEC Filing
Instil Bio Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Instil Bio Q3 Basic EPS USD -3.54
Instil Bio Inc expected to post a loss of $2.11 a share - Earnings Preview
Brief: Immuneonco Biopharmaceuticals Announces Registrational Strategy In Collaboration With Instil
Brief: Instil Bio And Immuneonco Announce Global Registrational Strategy For Pd-L1xvegf Bispecific Antibody, Syn-2510/Imm2510, In Non-Small Cell Lung Cancer And Triple-Negative Breast Cancer
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Received Near-Term Payment Of $5 Mln From Synbiotx
Instil Bio Inc reports results for the quarter ended in June - Earnings Summary
Brief: Instil Bio Q2 Basic EPS USD -2.29
Instil Bio Inc expected to post a loss of $2.98 a share - Earnings Preview
Instil Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Instil Bio Q1 Basic EPS USD -3.74
Instil Bio Inc expected to post a loss of $2.23 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Cheesecake Factory, Netflix, Texas Roadhouse
Brief: Instil Bio Says Due To Workforce Reduction, Co No Longer Expects To Report Clinical Data From ITIL-306-202 Clinical Trial In 2024